In:
Cancer, Wiley, Vol. 126, No. 14 ( 2020-07-15), p. 3237-3243
Abstract:
In this randomized clinical trial of patients with cetuximab‐refractory, recurrent/metastatic head and neck squamous cell carcinoma, cetuximab and temsirolimus induced durable responses in some patients (including 1 complete response), and this indicates modest clinical activity. However, in an unselected population, temsirolimus and cetuximab do not improve survival, although further investigation of the combination as a salvage option for patients with prior benefit from cetuximab monotherapy may be warranted.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v126.14
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1